NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
Tadepally Lakshmikanth(Hammersmith Hospital), Francesco Colucci(University of Cambridge), Klas Kärre(Karolinska Institutet), Roberto Biassoni(Istituto Giannina Gaslini), Veronika Groh(Fred Hutch Cancer Center), Kazuko Shibuya(University of Tsukuba), Viktor Umansky(Heidelberg University), Soldano Ferrone(Massachusetts General Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Francesco Ursini(Istituto Ortopedico Rizzoli), Daniela Pende(Ospedale Policlinico San Martino), Silvia Kimpfler(German Cancer Research Center), Loredana Ruggeri(University of Perugia), Petter Höglund(Karolinska University Hospital), Annette Paschen(University of Duisburg-Essen), Antje Sucker(German Cancer Research Center), Talib Hassan Ali(Magna Graecia University), Andrea Velardi(University Niccolò Cusano), Marusca Capanni(University of Perugia), Akira Shibuya(ShinEtsu Chemical (Japan)), Masashi Kato(Chubu University), Ennio Carbone(University of Naples Federico II), Shannon Burke(Babraham Institute), Andrea Anichini(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 331
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
|Nature|1986|2.1k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k